Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL912303 | 1.00 | DRD2 (0.47) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL13202379 | 1.00 | DRD2 (0.47) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL22844241 | 0.91 | BTK (0.51) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL227251 | 0.87 | DRD2 (0.45) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL227250 | 0.87 | DRD2 (0.45) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL25918883 | 0.87 | DRD2 (0.45) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL6883509 | 0.86 | DRD2 (0.48) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL6883508 | 0.86 | DRD2 (0.48) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL622419 | 0.86 | BTK (0.51) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL1543495 | 0.86 | BTK (0.51) | DRD2BTKEPHX1KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094267-B1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-04-22 | — | — | EP | disclosed |
| US-8247441-B2 | Chromene compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-08-21 | — | — | US | disclosed |
| US-8044044-B2 | 4-(1-amino-ethyl)-cyclohexylamine derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-25 | — | — | US | disclosed |
| US-20110021490-A1 | Chromene compounds, a process for their preparationand pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-01-27 | — | — | US | disclosed |
| US-20100029623-A1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-1489078-B1 | BENZOFURAN DERIVATIVE | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-01-06 | — | — | EP | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-7531537-B2 | Benzofuran derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1966142-A2 | NEW PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007072092-A2 | NEW PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
| US-20050282808-A1 | Benzofuran derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-12-22 | — | — | US | disclosed |
| EP-1489078-A1 | BENZOFURAN DERIVATIVE | Tanabe Seiyaku Co., Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282808-A1 | Benzofuran derivative | F12, F2, F11 | DRD2 2069/4885BTK 25/4885EPHX1 3082/4885 |
| US-20090209511-A1 | Benzofuran Derivatives | F12, F2, F3 | DRD2 2276/4885BTK 24/4885EPHX1 3031/4885 |
| US-20100029623-A1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | AHR, KRAS, CNKSR1 | DRD2 53/4885BTK 2517/4885EPHX1 2373/4885 |
| US-20110021490-A1 | Chromene compounds, a process for their preparationand pharmaceutical compositions containing them | CHRM3, CCKAR, ADRB3 | DRD2 239/4885BTK 1359/4885EPHX1 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.